Mid-2026 Travel Health Watch: The Outbreaks Every Traveller Should Have on Their Radar

A Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo has prompted a CDC Level 3 warning — "reconsider non-essential travel." Bundibugyo is a member of the same family as Ebola and causes a viral haemorrhagic fever with a significant fatality rate. For most business and leisure travellers, the practical risk of infection remains low because transmission requires direct contact with the bodily fluids of infected people or contaminated materials — but the presence of a Level 3 warning materially changes the calculus for any organisation with operations, NGO field teams, or travel plans in the affected regions. The correct response is not blanket avoidance of the entire country, but precise, location-specific assessment: which provinces are affected, whether the itinerary intersects them, what healthcare evacuation options exist, and whether the trip is genuinely essential. Field teams in particular need briefing on transmission routes, hygiene protocols, and symptom recognition.

Chikungunya — a mosquito-borne viral disease causing fever and often debilitating, long-lasting joint pain — is experiencing notable transmission across several territories in 2026, including parts of the Americas (Costa Rica, French Guiana, Bolivia), the Indian Ocean (Mauritius, Seychelles), and Suriname. The disease is spread by Aedes mosquitoes, the same daytime-biting vector responsible for dengue and Zika, which means the same preventive discipline applies: repellent, covered clothing, treated accommodation, and awareness that peak biting occurs during daylight hours, not just at dusk. Chikungunya is rarely fatal but can incapacitate a traveller for weeks and, in some cases, cause joint symptoms that persist for months — a serious consideration for anyone travelling for work. Travellers to affected regions should treat mosquito-bite prevention as a primary, not optional, measure.

Diphtheria — a vaccine-preventable bacterial infection that many in high-income countries consider a disease of the past — has resurged in regions where health systems and routine immunisation have been disrupted, including Haiti and parts of the Sahel. For travellers, the risk is concentrated in areas with low vaccination coverage and strained healthcare, and it is almost entirely preventable through vaccination. The practical implication is simple but frequently overlooked: travellers heading to affected regions should confirm their diphtheria vaccination (typically combined with tetanus) is current, ideally within the last ten years. This is one of the clearest examples of why a structured pre-travel health review matters — a lapsed booster is invisible until it is relevant, and by then the traveller is already in a location where treatment may be difficult to access.

Malaria remains one of the most serious health threats to travellers, and 2026 has seen rising transmission in areas including Yemen and the Indian Ocean territory of Mayotte. Climate shifts, conflict-driven breakdowns in vector control, and population displacement are expanding the map of where malaria transmission occurs — including into areas not historically flagged in older travel-health guidance. Malaria is both preventable and, if caught early, treatable, but it can become life-threatening within 24 hours of symptom onset. Effective protection combines chemoprophylaxis (antimalarial medication appropriate to the region and its resistance profile), rigorous mosquito-bite prevention, and — critically — awareness that any fever within a year of travel to an endemic area must be treated as potential malaria until proven otherwise. Relying on outdated destination risk profiles is a genuine hazard as the transmission map shifts.

What links these otherwise unrelated outbreaks is not the pathogens but the systems around them. In every case, the severity of the risk to a traveller depends heavily on where they are, how quickly they can recognise symptoms, and whether they can access competent medical care in time. Many of the affected regions have strained or under-resourced health systems, which means the assumption that "I can just see a doctor if I get sick" does not hold. This is where organisations most often fall short: they focus on the security dimension of travel risk while treating health as the individual traveller's responsibility. A credible programme includes pre-travel medical clearance for higher-risk destinations, confirmed medical evacuation coverage, a clear protocol for accessing care in-country, and 24/7 access to medical advice. Health is not separate from travel risk — for many destinations it is the dominant risk.

The organisations that manage travel health well do not treat it as a series of one-off reactions to outbreak headlines. They build it into the standard pre-travel workflow so that every trip to a relevant destination automatically triggers the right checks: a review of current CDC and WHO advisories for the specific itinerary, confirmation of required and recommended vaccinations with enough lead time to be effective, appropriate prophylaxis where indicated, a mosquito-bite prevention brief for vector-borne disease zones, and verification of medical and evacuation cover. The lead time matters enormously — many vaccinations require weeks to confer protection, and antimalarials often must begin before departure. A health check bolted on the day before a flight is largely theatre. Integrated properly, travel health protection is inexpensive, low-friction, and one of the highest-return components of any duty-of-care programme.